Pixantrone

Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it was notified by the European Medicines Agency ("EMEA") that pixantrone is eligible to be submitted for a Marketing Authorization Application ("MAA") through...

Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review

Completed NDA submission could lead to marketing approval in Q4-2009 SEATTLE, June 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administratio...

Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009

Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009. "Our focus for the first half of 2009 was to in...

Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone

CTI to Request Priority Review SEATTLE, April 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it began a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or...

European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application

...gulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 200...aceutical industry in general, and with OPAXIO and pixantrone in particular, including, without limitation, the potential for OPAXIO and pixantrone to be proved safe and effective the treatment of t...

Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding

...y a more attractive opportunity for biotechnology investors and position us well as we move to complete the submission of our New Drug Application for pixantrone to treat relapsed and refractory, aggressive non-Hodgkin's lymphoma to the U.S. Food and Drug Administration this month." The Company expects to ...

Pixantrone Overview in Non-Hodgkin's Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference

...ard Van der Jagt, M.D. of Ottawa Hospital will be presenting an overview of pixantrone clinical studies in non-Hodgkin's lymphoma at the 2009 Pan Pacific Lymphoma... 2009 Pan Pacific Lymphoma Conference pixantrone Presentation: Monday, June 22, 2009 ...

Pixantrone Now Available in Europe on a Named-Patient Basis

...s and IDIS Partner to Accelerate Patient Access to pixantrone through Program SEATTLE, May 5 /PRNewswire-Fi... (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. pixantrone will be supplied by IDIS to healthcare professiona...

CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center

...ging its two late-stage drug candidates OPAXIO and pixantrone to market as quickly as possible. The global ...h the Trade Unions in the near future. About pixantrone pixantrone (BBR 2778), a DNA intercalating anti-tumor agent t...

Craig W. Philips Takes Helm at CTI

...xpand the market indication for Zevalin(R), report pixantrone pivotal trial results, and potentially file a NDA,...ggressive NHL in the second half of 2008. Positive pixantrone data could allow CTI to submit an application for ...with interim data results expected in late 2009. pixantrone is an investigational agent under development for ...

Pixantrone in Medical Technology

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan ...

Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options

SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase III clinical data that were presented at American Society of Clinical Oncology (ASCO) 2009 Annual Meeting on June 1, 2009 is now available at Cli...

Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma

SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data from the phase III trial of pixantrone provides further support for a robust clinical benefit for pixantrone when used as single agent therapy in the ...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher Compared to Standard Chemotherapy SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its pha...

Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial

Novartis notified of data set closing, Top-line results expected in November SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary e...

Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL

Potential NDA Submission in 2009 SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) announced today that enrollment is complete in the phase III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with relapsed di...

Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)

Fast Track-Designated Study Approved Under FDA Special Protocol Assessment Process Could Expand Indication to Indolent NHL SEATTLE, Sept. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) today announced the launch of its phase III clinical trial, know...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trial anticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced the publication of preclinical studies, which demonstrate that treatment with pixantrone (BBR 2778) resulted in minimal o...

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its...

Pixantrone in Biological Technology

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the second quarter and six months ended June 30, 2009. "The second quarter of 2009 was a transforming quarter for the Co...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantr...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is seeking to obtain two new drug approvals...

Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission

Significant Difference in Primary Endpoint Could be Acceptable With Fewer Patients Than Originally Planned SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ) (MTAX: CTIC) announced today that following discussions with the U.S. Food and ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

...esults of CTI's EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refrac...l. "These results represent a breakthrough in that pixantrone could extend our ability to use a highly active an...sease) trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressi...

CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture

...at could affect the ongoing development of the Company's products such as pixantrone and OPAXIO include risks associated with preclinical and clinical develop...onal capital to continue to fund its operations, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as det...

Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market

...our submission of a New Drug Application (NDA) for pixantrone for aggressive relapse non-Hodgkin's lymphoma in t...ity to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-H...

Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders

...D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we ...uncertainties that could affect the development of pixantrone include risks associated with preclinical and clin...the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ...

Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference

...h 18th . Mr. Philips' highlights focused on CTI's pixantrone program for treatment of aggressive relapsed non-H... CTI based on third-party market research that, if pixantrone were approved in late 2009 by the FDA in the US, a...ositive results from the phase III EXTEND trial of pixantrone in aggressive relapsed NHL for which it met the tr...

Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results

...ximately 50% in 2009 CTI expects to complete pixantrone NDA submission in Q2 2009 SEATTLE, March 16 ... Met primary endpoint in the Phase III study of pixantrone in relapsed, aggressive non-Hodgkin's lymphoma with patients treated with pixantrone achieving a high rate of confirmed and unconfirmed...